Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."

TSX:TST - Post Discussion

TELESTA THERAPEUTICS INC > Must be April Fools' Day?!?...
View:
Post by rgonlyfactspls on Apr 01, 2015 1:52pm

Must be April Fools' Day?!?...

Makes no sense to me why there would not be more interest in TST (in a positive way) after the Bristol Conference call. - Was a pleasant surprise to hear the cost per dose is now estimated to be potentially "north of $4,000". That has been revised up by 33%+ since the AGM when it was quoted at $3,000/dose. - Was also very interesting to hear the significance of the "median duration of 33 months". - Presentation was made with a quiet confidence. Liked pretty much all I heard. - However, MAYBE more investors need to be aware of the new Telesta story?!? Still waaaaaiting for the launch of a meaningful PR campaign. rg
Comment by ChiefCommander1 on Apr 01, 2015 2:12pm
This post has been removed in accordance with Community Policy
Comment by loveshackdave on Apr 01, 2015 3:04pm
The target of this presentation is institutional investors. I wouldn't think that they won't just buy immediately after hearing this presentation. If they are interested, they probably have some research to do before they start buying and affecting the SP.
Comment by rgonlyfactspls on Apr 01, 2015 3:43pm
"On behalf of our Clients, Bristol works with thousands of professional institutional buy side investors, sell side analysts, money managers, family offices, investment advisors and stock brokers throughout the United States, Canada and Europe." - Who knows how the #s are skewed. Nomatter, PR, heightened awareness, never hurts and particularly helpful for the latter group as additional ...more  
Comment by DamnYankees on Apr 01, 2015 3:54pm
I was expecting more. This is a submission stage cancer drug valued below 50 mil, which has publicly stated that they are reviewing multiple offers from multiple partners. Surely you would expect there to be some immediate uptake when a partership, sale or BLA submission could happen any day. Instead the SP retreats on weak volume.
Comment by loveshackdave on Apr 01, 2015 4:36pm
The market cap is above $50M I'll have you know! SP is up nearly 20% in a month where IBB is at barely break even. Today's pullback will be recovered soon.
Comment by DamnYankees on Apr 01, 2015 4:49pm
The market cap is about 47 mil US and the stock  took a pounding on the US exchange today. This shouldn't come as news but no one really cares about Canadian market cap Shack. The folks controlling the share price happen to know that the only cap that counts is US and your sub 50 mil and short on cash profile is far too risky for most. That is why you are enjoying the mid 30 cent CANADIAN ...more  
Comment by loveshackdave on Apr 01, 2015 5:11pm
It seems to me that the TSE is a more reliable indicator of the actual market cap than the OTC since volume is over 4x higher on that exchange but either way, you're right it's still under $50M USD, barely. At any rate, I doubt there will be much of a divergence between the SP on the two for long.
Comment by 18tee20 on Apr 01, 2015 6:36pm
Give it some time. Combine this new exposure from todays Bristol conference with the upcoming MCNA pivotal study article that should be coming out any day in the Journal of Urology, and it is very likely to attract new investors over the coming weeks. Potentially very significantly so... "On behalf of our Clients, Bristol works with thousands of professional institutional buy side investors ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities